26 February 2015 - Deborah Wilkes
Archived
Novartis Consumer Health is seeking to switch its Otrivine Extra Dual Relief Nasal Spray, which contains xylometazoline hydrochloride and ipratropium bromide, from prescription-only to pharmacy (P) status in the UK.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.